within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DD10_Cefetamet;

model Cefetamet
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.5,
    Cl = 1.916666666666667e-06,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.0188,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.009666666666666665,
    Tlag = 10.200000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Cefetamet</td></tr><tr><td>ATC code:</td><td>J01DD10</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>18.8</td><td>L</td></tr>
    <tr><td>clearance:</td><td>6.9</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cefetamet is an oral third-generation cephalosporin antibiotic used primarily for treatment of respiratory and urinary tract infections caused by susceptible bacteria. It is not widely approved or in common clinical use today, having largely been replaced by other agents in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Blouin, RA, et al., &amp; Stoeckel, K (1989). Pharmacokinetics of intravenous cefetamet (Ro 15-8074) and oral cefetamet pivoxil (Ro 15-8075) in young and elderly subjects. <i>Antimicrobial agents and chemotherapy</i> 33(3) 291–296. DOI:<a href=\"https://doi.org/10.1128/AAC.33.3.291\">10.1128/AAC.33.3.291</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2729925/\">https://pubmed.ncbi.nlm.nih.gov/2729925</a></p></li><li><p>Holford, NH, et al., &amp; Stoeckel, K (1992). Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil. <i>Journal of pharmacokinetics and biopharmaceutics</i> 20(5) 421–442. DOI:<a href=\"https://doi.org/10.1007/BF01061464\">10.1007/BF01061464</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1287195/\">https://pubmed.ncbi.nlm.nih.gov/1287195</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01DD10 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Cefetamet;
